Fundraising Fox

Dewpoint Therapeutics

Boston, US · Founded 2018 · Delaware corporation · 6 known investors

dewpointx.com ↗
Biotechin /dewpointtherapeutics

Founders & leadership

RB
Regina Barzilay, Ph.D.Director
GA
Guiseppe A. Ciaramella, Ph,D.Director
MM
Mark Murcko, Ph.D.Director
AH
Amir H. Nashat, Ph.D.Director
OB
Olivier Brandicourt, M.D.Director
RY
Richard Young, Ph.D.Director
EL
Elisabeth LeidermanExecutive Officer
AN
Ameet Nathwani, M.D.Executive Officer, Director
IK
Isaac Klein, M.D., Ph.D.Executive Officer
SA
Srinivas Akkaraju, M.D., Ph.D.Director
LE
Lori EscobedoExecutive Officer
FP
Fabio Pucci, Ph.D.Director

Investors · 6

3E Bioventures CapitalPalo Alto
ARCH Venture PartnersChicago · $50K – $250M
EcoR1 CapitalSan Francisco
Samsara BioCapitalPalo Alto
Maverick VenturesreportedSan Francisco · $3M – $10M
Polaris PartnersreportedBoston · $500K – $5Mvia Amir Nashat · board

Reported raises · per SEC filings

Form D private placements
▶$77.2MraisedJul 2026 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ameet Nathwani, M.D.Executive Officer, Director
  • Srinivas Akkaraju, M.D., Ph.D.Director
  • Regina Barzilay, Ph.D.Director
  • Olivier Brandicourt, M.D.Director
  • Giuseppe A. Ciaramella, Ph.D.Director
  • Anthony Hyman, Ph.D.Director
  • Mark Murcko, Ph.D.Director
  • Amir H. Nashat, Sc.D.Director
  • Steven Neier, Ph.D.Director
  • Richard A. Young, Ph.D.Director
  • Isaac Klein, M.D., Ph.D.Executive Officer
Offering amount
$82.3M
Amount sold
$77.2M
First sale
Sep 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$150MraisedFeb 2022 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Anthony A. Hyman, Ph.D.Director
  • Giuseppe Ciaramella, Ph.D.Director
  • Joel D. SendekExecutive Officer
  • Srinivas Akkaraju, M.D., Ph.D.Director
  • Mark Murcko, Ph.D.Director
  • Lori EscobedoExecutive Officer
  • Ameet Nathwani, M.D.Director, Executive Officer
  • Olivier Brandicourt, M.D.Director
  • Juergen Eckhardt, M.D.Director
  • Richard Young, Ph.D.Director
  • Amir H. NashatDirector
  • Isaac A. Klein, M.D., Ph.D.Executive Officer
  • Regina Barzilay, Ph.D.Director
Offering amount
$150M
Amount sold
$150M
First sale
Jan 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$77.1MraisedNov 2020 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard A Young, Ph.D.Director
  • Ameet Nathwani, M.D.Director, Executive Officer
  • Mark Murcko, Ph.D.Director
  • Jurgen Eckhardt, M.D.Director
  • Bruce BeutelExecutive Officer
  • Srinivas Akkaraju, M.D.Director
  • Oliver Brandicourt, M.D.Director
  • Giuseeppe Ciaramella, Ph.D.Director
  • Amir H. NashatExecutive Officer, Director
  • Anthony A. Hyman, Ph.D.Director
Offering amount
$77.1M
Amount sold
$77.1M
First sale
Jul 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.